ENVALITH
住友ファーマ株式会社 logo

Sumitomo Pharma Co., Ltd.

4506・Prime Market・Pharmaceuticals

Official website
住友ファーマ株式会社 logo
Sumitomo Pharma Co., Ltd.4506

Business

Sumitomo Pharma Co., Ltd. is a research-driven pharmaceutical company founded in 1897. It manufactures and sells prescription pharmaceuticals across three segments: Japan, North America, and Asia, with revenue of ¥453,294 million for FY2026 (ending March 2026). North America accounts for 74.5% of consolidated revenue, driven by three core products: Orgovyx for advanced prostate cancer, Gemtesa for overactive bladder, and Myfembree for uterine fibroids and endometriosis. In Japan, the company operates a product portfolio in the diabetes and CNS/psychiatric therapeutic areas, and in March 2026 obtained manufacturing and marketing approval for Amshepri (Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cells), the world's first iPS cell-derived product. The company aims to establish its position as a "Global Specialized Player (GSP)" by 2033.

Business Model

The North American subsidiary Sumitomo Pharma America, Inc. sells its three core products directly and distributes them through three major wholesalers (Cencora, McKesson, and Cardinal Health). In Japan, in addition to its proprietary products, the company markets promotion-partnered products with Janssen Pharmaceutical and Novo Nordisk, with royalty and milestone income also serving as a revenue source. The company advocates a "value creation cycle" in which R&D expenditure is concentrated to nurture the pipeline, and post-launch product revenue is reinvested into next-generation development.

Company Strengths

In FY2026 (ending March 2026), North America revenue was ¥337,923 million (up 34.2% year on year), and core segment profit was ¥75,742 million (up 77.8% year on year). In August 2025, the company directly acquired substantially all assets, including patent rights, for its three core products, establishing a structure for direct involvement in business operations. Orgovyx also recorded sales milestone income, improving both the quality and quantity of revenue.

In March 2026, the company obtained manufacturing and marketing approval (conditional and time-limited approval) for Amshepri (Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cells). This is the world's first approved iPS cell-derived regenerative and cellular medicine product, establishing a first-mover advantage in the treatment of Parkinson's disease. Phase 1/2 trials are also underway in the United States, providing a foundation for global expansion.

After recording a substantial loss in fiscal year 2023, the company carried out a fundamental structural reform, including significant workforce reductions. Ongoing effects of business structure improvement measures, such as early retirement programs, led to continued reductions in selling, general and administrative expenses, resulting in a substantial profit increase, with core operating profit of ¥105,900 million (up 145.4% year on year) in FY2026 (ending March 2026). The financial targets of Reboot 2027 are now expected to be achieved ahead of schedule.

ENVALITH's Perspective

Of the ¥106,865 million profit attributable to owners of parent for FY2026 (ending March 2026), a ¥49,043 million gain on transfer of Asia business equity has been recorded under "other income." Although the gap versus core operating profit of ¥105,908 million, which reflects recurring earnings power, is small, the FY2027 (ending March 2027) forecast calls for a decline in profit, with core operating profit of ¥91,000 million (down 14.1% year on year) and profit attributable to owners of parent of ¥77,000 million (down 27.9% year on year), making it necessary to assess the underlying earnings power once one-time factors have receded.

The FY2027 (ending March 2027) revenue forecast of ¥540,000 million (up 19.1% year on year) is premised on the recognition of sales milestone income upon Orgovyx reaching annual sales of US$1 billion. There is an uncertain external environment stemming from factors such as U.S. pricing policy, tariff measures, and conflict-related cost increases, and if the milestone is not achieved, downside risk to the earnings forecast could materialize. The foreign exchange assumption of ¥155 to the US dollar also assumes a weaker yen than the actual rate (¥150.67), embedding foreign exchange risk as well.

The public offering in April 2026 (51,304,400 shares, total paid-in amount of ¥97,842 million) strengthened the financial base, but the increase in share count (dilution of approximately 12.9%) will dilute earnings per share. Proceeds are planned to be allocated to oncology R&D (¥30,000 million), neurodegenerative diseases and infectious diseases (¥10,000 million), and regenerative and cell medicine (¥10,000 million), among others. Progress in the Phase 2 trials of enzomenib and nuvisertib and whether early approval can be obtained will be the most critical monitoring items affecting mid- to long-term corporate value. Dividends remain undecided for FY2027 (ending March 2027) as well, and the timing of any resumption of shareholder returns is also a point of attention.

Growth Strategy

Establishing global specialty pharma (GSP) status through maximizing the value of the three core North America products and achieving early approval of the oncology and regenerative medicine pipeline

Continuing to promote the competitive advantages of Orgovyx, Gemtesa, and Myfembree while optimizing the sales organization. In FY2027 (ending March 2027), the company anticipates recording milestone sales revenue when Orgovyx's annual sales reach US$1 billion, aiming for further expansion of North America revenue.

Enzomenib has begun a Phase 2 monotherapy trial (confirmatory trial) targeting acute leukemia in the US and Japan. Nuvisertib is advancing a Phase 1/2 trial targeting myelofibrosis. Development will be accelerated through expansion of clinical trial sites into Europe and Asia, with partnerships also being considered at the appropriate timing.

For Amshepri, which received manufacturing and marketing approval (conditional and time-limited approval) in Japan in March 2026, post-marketing clinical trials and post-marketing surveillance will be conducted with the aim of obtaining full approval. A Phase 1/2 trial is also being advanced in the US. Development of allogeneic iPS cell-derived retinal pigment epithelial cells and retinal sheets is proceeding in parallel.

Focusing on expanding sales of Xeplion/Xeplion TRI (for which the company has handled distribution since January 2026) and Ozempic Subcutaneous Injection/Wegovy Subcutaneous Injection (co-promotion with Novo Nordisk). Together with maximizing the value of Twymeeg and Latuda, this will offset the revenue decline from the end of exclusive distribution of Equa/Eucreas.

Proceeds from the April 2026 public offering (total paid-in amount of ¥97,842 million) will be allocated to oncology R&D (¥30,000 million), neurodegenerative disease R&D and other (¥10,000 million), regenerative cell medicine R&D (¥10,000 million), and capital expenditures and other (¥10,000 million), with the remainder used to repay interest-bearing debt. A financial structure independent of Sumitomo Chemical's debt guarantees has also been established.

Last updated: July 19, 2026